FDA Updates Approval for Lobrena to First Line Treatment for Advanced NSCLC Patients with Changes in ALK

[Miranda_GO2]

On March 3rd, 2021, the Food and Drug Administration (FDA) approved Lobrena (lorlatinib) for the first line treatment of non-small cell lung cancer (NSCLC) which has spread outside of the lungs that has a change in ALK identified by an FDA approved test. The FDA based their approval on the results of a clinical trial which found that patients receiving Lobrena went longer before experiencing progression than those who received Xalkori (crizotinib). Lorbrena had already been approved for ALK+ lung cancer, but this approval makes Lorbrena accessible for newly diagnosed patents with the ALK+ mutation found through biomarker testing.

The FDA’s updated approval of Lobrena gives people with lung cancer a new choice for first-line treatment.

Here is the full press release: fda.gov/drugs/drug-approval...

[Denzie Moderator Volunteer]

We seem to be entering another one of those phases where they’re coming weekly. This is so heartening. I hope it helps so many.